Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
about
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsEpigenetic regulators and their impact on therapy in acute myeloid leukemiaTrials with 'epigenetic' drugs: an updateHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Current therapy of myelodysplastic syndromesThe oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsThe combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemiaEpigenetic-based therapies in cancer: progress to date.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Toxicological and metabolic considerations for histone deacetylase inhibitors.Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacinCD99/MIC2 Constitutes a Differentiation Antigen of a Human Osteoblast Cell Line.Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
P2860
Q24633763-B665918D-6389-43AE-B4C4-966539DA839BQ26765402-CBEDFE1C-BABB-47DE-87CF-1A23EC5D0069Q27000542-382362BE-121A-4D7F-B502-604E60D93BF4Q30251920-4B38CA9B-1138-48B5-A0EC-1C8DD3E5395AQ34013796-6D653D66-A3B6-498D-A189-B272830A3D88Q34640790-AF604E75-F2AA-4C64-BE34-9B267F6BB968Q35051547-B68D11FB-CAE4-4ABD-9346-425814323F3AQ35930622-B60913C5-10F0-4EF0-ACDD-D3FFD6BB6E4FQ36444091-4AAEA1B3-8891-4E56-AAF0-245024304266Q37153361-05139147-896A-4998-8197-D210124D3623Q37964702-780A6923-70CF-4F87-9873-FD7CA49787F2Q38012499-B51EEA8E-76C6-41D9-95CB-E95B1AD0472AQ38071321-55B9AC27-F8CE-43E5-ACE6-C9C2027DD6FCQ38597973-4580A953-2F22-4E3F-A2E2-C5194032BA36Q38710509-45B13ABF-42F9-4D3F-896E-2DB9FC16DB39Q38961023-F90090DF-C881-4302-B3B5-E11AC538B2C5Q42649800-BAE674D8-E9BE-43C1-93D8-39D94749EEC6Q43839408-F9E2B958-A93E-45D7-B866-500520744CECQ48151417-679C9FDA-60F7-42E3-82B8-15A432C30004Q49167307-46BB5AF5-A8DC-4C10-90BF-A6EF88274AD1Q57167105-D423F941-CEEB-4333-ACBD-8ED7873AA526
P2860
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@en
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@nl
type
label
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@en
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@nl
prefLabel
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@en
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@nl
P2860
P1476
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
@en
P2093
Norbert Vey
P2860
P304
P356
10.1517/13543784.2011.542750
P407
P577
2010-12-31T00:00:00Z